| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Malady Kyle | Director | 6340 SEQUENCE DRIVE, SAN DIEGO | /s/ Jereme M. Sylvain, as Attorney-in-Fact for Kyle Malady | 2025-09-09 | 0001760581 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DXCM | Common Stock | Sale | -$53.9K | -667 | -2.86% | $80.86 | 22.7K | Sep 5, 2025 | Direct | F1, F2 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | On June 6, 2025, Mr. Malady adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Malady. The shares set forth above were sold pursuant to the 10b5-1 Plan. |
| F2 | Included in this number are 5,192 unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. |
Exhibit 24 - Power of Attorney